|
| Friday, 29 May 2020, 10:31 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
|
| In Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma to be Presented at 2020 ASCO Annual Meeting |
TOKYO, May 29, 2020 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. known as MSD outside the United States and Canada, today announced that results from two trials evaluating LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A., will be presented at the American Society of Clinical Oncology (ASCO20 Virtual Scientific Program) from May 29 to 31, 2020. The two trials, Study 116/KEYNOTE-524 and Study 111/KEYNOTE-146, examined patients with unresectable hepatocellular carcinoma (HCC) with no prior systemic therapy and patients with metastatic clear cell renal cell carcinoma (ccRCC) who progressed following immune checkpoint inhibitor therapy, respectively.
"The tumor response rates demonstrated with KEYTRUDA plus LENVIMA in these studies underscore the potential of this combination regimen in certain types of hepatocellular and renal cell carcinoma," said Dr. Jonathan Cheng, Vice President, Oncology Clinical Research, Merck & Co., Inc., Kenilworth, N.J., U.S.A. Research Laboratories. "KEYTRUDA plus LENVIMA is an important pillar of our broad oncology research program, and we continue to advance the study of the combination across multiple types of cancers and stages of disease."
"As data from our combination trials continue to read out, our enthusiasm for and belief in the potential of LENVIMA plus KEYTRUDA are strengthened by the growing body of evidence observed in multiple advanced cancers," said Dr. Takashi Owa, Chief Medicine Creation and Chief Discovery Officer, Oncology Business Group at Eisai. "Our ongoing clinical study efforts on this combination exemplify our commitment to following the science and exploring possible solutions for patients affected by difficult-to-treat cancers."
Results from Study 116/KEYNOTE-524 (Abstract #4519) are being presented in a poster discussion session, and results from Study 111/KEYNOTE-146 (Abstract #5008) are being presented in an oral abstract session of the virtual scientific program of the 2020 ASCO Annual Meeting.
For the full details, visit https://www.eisai.com/news/2020/pdf/enews202023pdf.pdf.
Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
